Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGNES-19 trial of Adrecizumab in moderate to severe COVID-19
2020-001336-10Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Dec 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Adrecizumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to clinical improvement. Started Dec 2021; status: completed.
02
Drugs
adrecizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001336-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001336-10.